<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04864834</url>
  </required_header>
  <id_info>
    <org_study_id>CSOK583A12301</org_study_id>
    <nct_id>NCT04864834</nct_id>
  </id_info>
  <brief_title>Phase III Study Assessing the Efficacy, Safety and Immunogenicity of SOK583A1 Versus Eylea® in Patients With Neovascular Age-related Macular Degeneration</brief_title>
  <acronym>Mylight</acronym>
  <official_title>A 52-week Multicenter, Randomized, Double-masked, 2-arm Parallel Study to Compare Efficacy, Safety and Immunogenicity of SOK583A1 to Eylea®, Administered Intravitreally, in Patients With Neovascular Age-related Macular Degeneration</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sandoz</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sandoz</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Purpose and rationale: To demonstrate similar efficacy, safety and immunogenicity of SOK583A1&#xD;
      and Eylea EU as per Eylea approved treatment regimen in patients with nAMD.&#xD;
&#xD;
      The primary clinical question of interest is: Does SOK583A1 have similar efficacy as Eylea EU&#xD;
      in terms of mean change in BCVA score in participants with nAMD who are anti-VEGF naive,&#xD;
      without important protocol deviations and adherent to the treatment and completed the&#xD;
      treatment to Week 8?&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      BCVA: Best-Corrected Visual Acuity Eylea EU: Europe-authorized Eylea® nAMD: Neovascular&#xD;
      Age-related Macular Degeneration VEGF: Vascular Endothelium Growth Factor&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 12, 2021</start_date>
  <completion_date type="Anticipated">May 5, 2023</completion_date>
  <primary_completion_date type="Anticipated">February 10, 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Best-Corrected Visual Acuity (BCVA) will be assessed using the ETDRS testing charts at an initial distance of 4 meters. The change from Baseline in BCVA in letters is defined as difference between BCVA score between Week 8 and Baseline.</measure>
    <time_frame>Change from baseline in mean BCVA score at Week 8</time_frame>
    <description>The primary aim of the study is to demonstrate equivalence of change in BCVA score from Baseline at Week 8 between participants with nAMD treated with SOK583A1 and participants treated with Eylea EU. The primary analysis will be performed on the Per-Protocol Set (PPS), which is the most appropriate analysis set to use when testing for equivalence.&#xD;
ETDRS: Early Treatment Diabetic Retinopathy Study EU: European</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>• To evaluate if the anatomical outcome of SOK583A1 is similar to Eylea EU</measure>
    <time_frame>Week 1, 4, 8, 24 and 52</time_frame>
    <description>• Mean change in CSFT using SD-OCT from Baseline to Week 1, 4, 8, 24 and 52&#xD;
CSFT: Central Subfield Thickness SD-OCT: Spectral-Domain Optical Coherence Tomography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>• To evaluate if the anatomical outcome of SOK583A1 is similar to Eylea EU</measure>
    <time_frame>Week 1, 4, 8, 24 and 52</time_frame>
    <description>• Mean change of CNV lesion size using FA from Baseline to Week 8 and 52&#xD;
CNV: Choroidal neovascularization FA: Fundus Angiography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>• To evaluate if the efficacy of SOK583A1 is similar to Eylea EU in terms of BCVA</measure>
    <time_frame>Week 24 and 52</time_frame>
    <description>• Mean change from Baseline in BCVA score using EDTRS testing charts at Week 24 and 52</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>• To evaluate if SOK583A1 is similar to Eylea EU in terms of safety</measure>
    <time_frame>52 weeks</time_frame>
    <description>• Incidence of ocular and non-ocular Adverse events (AEs) over 52 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>• To evaluate if SOK583A1 is similar to Eylea EU in terms of immunogenicity</measure>
    <time_frame>Week 52</time_frame>
    <description>• Development of binding and neutralizing Anti-drug antibodies (ADAs) up to Week 52</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>• To evaluate the systemic exposure of SOK583A1 and Eylea EU in participants of the Pharmacokinetic (PK) assessment</measure>
    <time_frame>Baseline (pre-dose) and 24 hours</time_frame>
    <description>• Aflibercept concentration assessments at Baseline (pre-dose) and 24 hours after the first and third injections</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">460</enrollment>
  <condition>Neovascular Age-related Macular Degeneration</condition>
  <arm_group>
    <arm_group_label>SOK583A1 (40 mg/mL)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravitreal (IVT) administration of 2 mg of SOK583A1 in the study eye, every 4 weeks (q4w) at Baseline, Week 4 and Week 8, and thereafter every 8 weeks (q8w) at week 16, 24, 32, 40 and 48.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Eylea EU (40 mg/mL)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>IVT administration of 2 mg of SOK583A1 in the study eye, every 4 weeks (q4w) at Baseline, Week 4 and Week 8, and thereafter every 8 weeks (q8w) at week 16, 24, 32, 40 and 48.&#xD;
EU: European</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>SOK583A1 (40 mg/mL)</intervention_name>
    <description>IVT administration of 2 mg of SOK583A1 in the study eye, every 4 weeks (q4w) at Baseline, Week 4 and Week 8, and thereafter every 8 weeks (q8w) at week 16, 24, 32, 40 and 48.</description>
    <arm_group_label>SOK583A1 (40 mg/mL)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Eylea EU (40 mg/mL)</intervention_name>
    <description>IVT administration of 2 mg of Eylea in the study eye, every 4 weeks (q4w) at Baseline, Week 4 and Week 8, and thereafter every 8 weeks (q8w) at week 16, 24, 32, 40 and 48.</description>
    <arm_group_label>Eylea EU (40 mg/mL)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Participants eligible for inclusion in this study must meet all of the following criteria:&#xD;
&#xD;
          1. Signed informed consent must be obtained prior to participation in the study&#xD;
&#xD;
          2. Participants must be 50 years of age or older at Screening&#xD;
&#xD;
          3. Anti-VEGF treatment-naive patients for either eye and systemically&#xD;
&#xD;
          4. Study eye diagnosed with active CNV lesions (type 1 and/ or type 2) secondary to AMD&#xD;
             and/or Retinal Angiomatous Proliferation lesions (type 3), affecting the central&#xD;
             subfield. Active CNV lesion is defined by the presence of leakage as evidenced by&#xD;
             fluorescein angiography, and intra- or subretinal fluid as evidenced by optical&#xD;
             coherence tomography, both confirmed by the CRC at Screening&#xD;
&#xD;
          5. Total area of CNV (including both classic and occult components) must comprise &gt; 50%&#xD;
             of the total lesion area in the study eye, confirmed by the CRC at Screening&#xD;
&#xD;
          6. BCVA between 73 and 38 letters, both inclusive, in the study eye at Screening and&#xD;
             Baseline using ETDRS testing charts&#xD;
&#xD;
          7. Willing and able to comply with all study procedures, and be likely to complete the&#xD;
             study&#xD;
&#xD;
          8. Clear ocular media and adequate pupil dilatation in both eyes to permit good quality&#xD;
             photographic imaging.&#xD;
&#xD;
        Participants meeting any of the following criteria are not eligible for inclusion in this&#xD;
        study.&#xD;
&#xD;
        Ocular conditions and treatments:&#xD;
&#xD;
          1. Previous treatment with any anti-VEGF therapy in either eye or investigational drugs&#xD;
             in study eye or fellow eye, at any time prior to Baseline&#xD;
&#xD;
          2. Participant has received any approved treatment for nAMD (other than vitamin and&#xD;
             dietary supplements) in the study eye and at any time prior to Baseline&#xD;
&#xD;
          3. Presence of other causes of CNV, including pathologic myopia (spherical equivalent of&#xD;
             -8 diopters or more negative, or axial length of 25 mm or more), ocular histoplasmosis&#xD;
             syndrome, angioid streaks, choroidal rupture, or multifocal choroiditis in the study&#xD;
             eye&#xD;
&#xD;
          4. Any active or suspected intraocular or periocular infection or suspected active&#xD;
             intraocular inflammation (e.g infectious conjunctivitis, keratitis, scleritis,&#xD;
             endophthalmitis, infectious blepharitis, uveitis) in either eye at Screening or&#xD;
             Baseline&#xD;
&#xD;
          5. Subfoveal fibrosis, atrophy, or scarring extending &gt; 50% of total lesion area in the&#xD;
             study eye as assessed by the Investigator at Screening and confirmed by the CRC prior&#xD;
             to randomization&#xD;
&#xD;
          6. Subretinal hemorrhage that is ≥ 50% of the total lesion area in the study eye, or if&#xD;
             the subretinal hemorrhage involving the fovea is 1 or more disc areas (≥ 2.54 mm2 ) in&#xD;
             size in the study eye, as assessed by Fluorescein Angiography (FA) and confirmed by&#xD;
             the CRC&#xD;
&#xD;
          7. Retinal pigment epithelium (RPE) rip/tear in the study eye at Screening or Baseline&#xD;
&#xD;
          8. Current vitreous hemorrhage or history of vitreous hemorrhage in the study eye within&#xD;
             4 weeks prior to Baseline&#xD;
&#xD;
          9. History or evidence of the following, in the study eye:&#xD;
&#xD;
               -  Intraocular (including cataract surgery) or refractive surgery within the 90 day&#xD;
                  period prior to Baseline. The yttrium aluminum garnet (YAG) posterior capsulotomy&#xD;
                  is allowed no later than 4 weeks prior to Baseline&#xD;
&#xD;
               -  Previous penetrating keratoplasty or vitrectomy&#xD;
&#xD;
               -  Previous panretinal photocoagulation&#xD;
&#xD;
               -  Previous photodynamic therapy&#xD;
&#xD;
               -  Previous submacular surgery or other surgical intervention for AMD&#xD;
&#xD;
               -  Retinal detachment or treatment or surgery for retinal detachment&#xD;
&#xD;
               -  Any history of macular hole of stage 2 and above&#xD;
&#xD;
               -  Prior trabeculectomy or other filtration surgery&#xD;
&#xD;
               -  Ocular trauma within the 6-months period prior to Baseline&#xD;
&#xD;
         10. History of hypersensitivity to any of the study treatments or its excipients, or&#xD;
             clinically relevant sensitivity to fluorescein dye, as assessed by the Investigators&#xD;
&#xD;
         11. Uncontrolled glaucoma in the study eye defined as intraocular pressure (IOP) &gt; 25 mmHg&#xD;
             on medication or according to Investigator's judgment at Screening or Baseline&#xD;
&#xD;
         12. Aphakia and/or absence of the posterior capsule in the study eye at Screening or&#xD;
             Baseline, unless it occurred as a result of a YAG posterior capsulotomy in association&#xD;
             with prior posterior chamber intraocular lens implantation&#xD;
&#xD;
         13. Intra or periocular use of corticosteroids in the study eye within a 6 month period&#xD;
             prior to Baseline&#xD;
&#xD;
         14. Use of topical ocular corticosteroids in the study eye for 30 or more consecutive days&#xD;
             within the 90 days period prior to Baseline&#xD;
&#xD;
         15. Previous therapeutic radiation near the region of the study eye&#xD;
&#xD;
         16. Concomitant conditions or ocular disorders in the study eye, including media&#xD;
             opacities, cataract and diabetic macular edema, at Screening or Baseline which could,&#xD;
             in the opinion of the Investigator, prevent response to study treatment or may&#xD;
             confound interpretation of study results (efficacy and safety), compromise visual&#xD;
             acuity or require medical or surgical intervention during the course of the study&#xD;
&#xD;
         17. Presence of amblyopia, amaurosis or ocular disorders with BCVA &lt;38 letters (ETDRS&#xD;
             testing charts) in the fellow eye at Screening (except when due to conditions whose&#xD;
             surgery may improve VA, e.g. cataract)&#xD;
&#xD;
         18. Presence of Scleromalacia in either eye&#xD;
&#xD;
         19. Participants requiring anti-VEGF treatment of the fellow eye at Baseline will not be&#xD;
             eligible for the PK substudy&#xD;
&#xD;
             Systemic conditions and treatments:&#xD;
&#xD;
         20. Previous systemic treatment with any anti-VEGF therapy&#xD;
&#xD;
         21. Use of systemic corticosteroids for 30 or more consecutive days within the 90 days&#xD;
             prior to Baseline, with the exception of low stable doses of corticosteroids (defined&#xD;
             as ≤ 10 mg prednisolone or equivalent dose used for 90 days or more).&#xD;
&#xD;
         22. Uncontrolled blood pressure defined as a systolic value ≥ 160 mmHg or diastolic value&#xD;
             ≥ 100 mmHg at Screening&#xD;
&#xD;
         23. Stroke or myocardial infarction during the 6-month period prior to Baseline&#xD;
&#xD;
         24. Participation in an investigational systemic drug, biologic, or device study within 30&#xD;
             days or duration of 5 half-lives of the investigational product (whichever is longer)&#xD;
             prior to Baseline. Note: observational clinical studies solely involving&#xD;
             over-the-counter vitamins, supplements, or diets are not exclusionary&#xD;
&#xD;
         25. Presence of infection at screening or active infection within 2 weeks before screening&#xD;
&#xD;
         26. Underlying advanced, severe and uncontrolled concomitant condition (including, but not&#xD;
             limited to metabolic, hematologic, renal, hepatic, pulmonary, neurologic, endocrine,&#xD;
             cardiac, inflammatory, infectious or gastrointestinal), physical examination finding,&#xD;
             or clinical laboratory finding which in the opinion of the Investigator place the&#xD;
             participant at unacceptable risk from participation in the study&#xD;
&#xD;
         27. History of a medical condition (including, but not limited to chronic disease&#xD;
             immunosuppression, metabolic dysfunction, prior exposure to other drugs that may pose&#xD;
             risk of infection or allergic reactions) that, in the judgment of the Investigator,&#xD;
             would preclude scheduled study visits, completion of the study, or a safe&#xD;
             administration of investigational product, or that might affect participant safety or&#xD;
             interpretation of the study results.&#xD;
&#xD;
         28. Pregnant or nursing (lactating) women and women of child-bearing potential, defined as&#xD;
             all women physiologically capable of becoming pregnant, unless they are using highly&#xD;
             effective methods of contraception while taking study treatment and for 3 months after&#xD;
             stopping the medication. Highly effective contraception methods include:&#xD;
&#xD;
               -  Total abstinence (when this is in line with the preferred and usual lifestyle of&#xD;
                  the participant. Periodic abstinence (e.g. calendar, ovulation, symptothermal,&#xD;
                  post-ovulation methods) and withdrawal are not acceptable methods of&#xD;
                  contraception.&#xD;
&#xD;
               -  Female sterilization (have had surgical bilateral oophorectomy with or without&#xD;
                  hysterectomy), total hysterectomy or tubal ligation at least six weeks before&#xD;
                  taking investigational drug. In case of oophorectomy alone, only when the&#xD;
                  reproductive status of the woman has been confirmed by follow up hormone level&#xD;
                  assessment.&#xD;
&#xD;
               -  Male sterilization (at least 6 months prior to screening). For female&#xD;
                  participants on the study, the vasectomized male partner should be the sole&#xD;
                  partner for that participant.&#xD;
&#xD;
               -  Use of oral (estrogen and progesterone), injected or implanted hormonal methods&#xD;
                  of contraception or other forms of hormonal contraception that have comparable&#xD;
                  efficacy (failure rate &lt;1%), for example hormone vaginal ring or transdermal&#xD;
                  hormone contraception or placement of an intrauterine device (IUD) or&#xD;
                  intrauterine system (IUS).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Sandoz</last_name>
    <phone>1-888-669-6682</phone>
    <email>novartis.email@novartis.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sandoz</last_name>
    <phone>+41613241111</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Sandoz Investigational Site</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigational Site</name>
      <address>
        <city>Arcadia</city>
        <state>California</state>
        <zip>91006</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigational Site</name>
      <address>
        <city>Campbell</city>
        <state>California</state>
        <zip>95008</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigational Site</name>
      <address>
        <city>Encino</city>
        <state>California</state>
        <zip>91436</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigational Site</name>
      <address>
        <city>Fullerton</city>
        <state>California</state>
        <zip>92835</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigational Site</name>
      <address>
        <city>Glendale</city>
        <state>California</state>
        <zip>91203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigational Site</name>
      <address>
        <city>Huntington Beach</city>
        <state>California</state>
        <zip>92647</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigational Site</name>
      <address>
        <city>Pasadena</city>
        <state>California</state>
        <zip>91107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigational Site</name>
      <address>
        <city>Poway</city>
        <state>California</state>
        <zip>92064</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigational Site</name>
      <address>
        <city>Redlands</city>
        <state>California</state>
        <zip>92374</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigational Site</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95841</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigational Site</name>
      <address>
        <city>Fort Myers</city>
        <state>Florida</state>
        <zip>33912-7125</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigational Site</name>
      <address>
        <city>Melbourne</city>
        <state>Florida</state>
        <zip>32904</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigational Site</name>
      <address>
        <city>Pinellas Park</city>
        <state>Florida</state>
        <zip>33782</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigational Site</name>
      <address>
        <city>Stuart</city>
        <state>Florida</state>
        <zip>34994</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigational Site</name>
      <address>
        <city>Winter Haven</city>
        <state>Florida</state>
        <zip>33880</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigational Site</name>
      <address>
        <city>Marietta</city>
        <state>Georgia</state>
        <zip>30060</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigational Site</name>
      <address>
        <city>Oak Forest</city>
        <state>Illinois</state>
        <zip>60452</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigational Site</name>
      <address>
        <city>Leawood</city>
        <state>Kansas</state>
        <zip>66211</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigational Site</name>
      <address>
        <city>Hagerstown</city>
        <state>Maryland</state>
        <zip>21740</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigational Site</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87102</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigational Site</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14620</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigational Site</name>
      <address>
        <city>Eugene</city>
        <state>Oregon</state>
        <zip>97401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigational Site</name>
      <address>
        <city>Rapid City</city>
        <state>South Dakota</state>
        <zip>57701</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigational Site</name>
      <address>
        <city>Abilene</city>
        <state>Texas</state>
        <zip>79606</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigational Site</name>
      <address>
        <city>Arlington</city>
        <state>Texas</state>
        <zip>76012</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigational Site</name>
      <address>
        <city>Willow Park</city>
        <state>Texas</state>
        <zip>70687</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigational Site</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigational Site</name>
      <address>
        <city>Lynchburg</city>
        <state>Virginia</state>
        <zip>24502</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigational Site</name>
      <address>
        <city>Waterford</city>
        <state>Wisconsin</state>
        <zip>06385</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigational Site</name>
      <address>
        <city>Albury</city>
        <state>New South Wales</state>
        <zip>2640</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigational Site</name>
      <address>
        <city>Liverpool</city>
        <state>New South Wales</state>
        <zip>2170</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigational Site</name>
      <address>
        <city>Parramatta</city>
        <state>New South Wales</state>
        <zip>2150</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigational Site</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigational Site</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigational Site</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3002</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigational Site</name>
      <address>
        <city>Linz</city>
        <state>Oberoesterreich</state>
        <zip>A 4020</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigational Site</name>
      <address>
        <city>Linz</city>
        <state>Upper Austria</state>
        <zip>4021</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigational Site</name>
      <address>
        <city>Sofia</city>
        <zip>1784</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigational Site</name>
      <address>
        <city>Varna</city>
        <zip>9002</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigational Site</name>
      <address>
        <city>Varna</city>
        <zip>9010</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigational Site</name>
      <address>
        <city>Marseille</city>
        <state>Bouches-Du-Rhone</state>
        <zip>13008</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigational Site</name>
      <address>
        <city>Saint Cys Sur Loire</city>
        <state>Indre Et Loire</state>
        <zip>37540</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigational Site</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigational Site</name>
      <address>
        <city>Budapest</city>
        <state>HUN</state>
        <zip>1204</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigational Site</name>
      <address>
        <city>Debrecen</city>
        <zip>4032</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigational Site</name>
      <address>
        <city>Sopron</city>
        <zip>H-9400</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigational Site</name>
      <address>
        <city>Szeged</city>
        <zip>H-6720</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigational Site</name>
      <address>
        <city>Lod</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigational Site</name>
      <address>
        <city>Nagoya</city>
        <state>Aichi</state>
        <zip>457 8510</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigational Site</name>
      <address>
        <city>Nagoya</city>
        <state>Aichi</state>
        <zip>466 8560</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigational Site</name>
      <address>
        <city>Fukuoka city</city>
        <state>Fukuoka</state>
        <zip>812-8582</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigational Site</name>
      <address>
        <city>Fukuoka-city</city>
        <state>Fukuoka</state>
        <zip>811-0213</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigational Site</name>
      <address>
        <city>Kobe-shi</city>
        <state>Hyogo</state>
        <zip>650-0017</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigational Site</name>
      <address>
        <city>Inashiki-gun</city>
        <state>Ibaraki</state>
        <zip>300-0395</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigational Site</name>
      <address>
        <city>Meguro-ku</city>
        <state>Tokyo</state>
        <zip>152-8902</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigational Site</name>
      <address>
        <city>Ube</city>
        <state>Yamaguchi</state>
        <zip>755-8505</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigational Site</name>
      <address>
        <city>Riga</city>
        <zip>1002</zip>
        <country>Latvia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigational Site</name>
      <address>
        <city>Riga</city>
        <zip>LV-1007</zip>
        <country>Latvia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigational Site</name>
      <address>
        <city>Kaunas</city>
        <state>Kauno Apskritis</state>
        <zip>50161</zip>
        <country>Lithuania</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigational Site</name>
      <address>
        <city>Vilnius</city>
        <zip>LT-08661</zip>
        <country>Lithuania</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigational Site</name>
      <address>
        <city>Krakow</city>
        <state>Malopolska</state>
        <zip>30-394</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigational Site</name>
      <address>
        <city>Bydgoszcz</city>
        <zip>85-631</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigational Site</name>
      <address>
        <city>Wroclaw</city>
        <zip>53-334</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigational Site</name>
      <address>
        <city>Coimbra</city>
        <zip>3000-548</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigational Site</name>
      <address>
        <city>Coimbra</city>
        <zip>3030-363</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigational Site</name>
      <address>
        <city>Zilina</city>
        <state>Slovak Republic</state>
        <zip>010 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigational Site</name>
      <address>
        <city>Bratislava</city>
        <zip>821 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigational Site</name>
      <address>
        <city>Bratislava</city>
        <zip>83301</zip>
        <country>Slovakia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigational Site</name>
      <address>
        <city>Trencin</city>
        <zip>91171</zip>
        <country>Slovakia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigational Site</name>
      <address>
        <city>Oviedo</city>
        <state>Asturias</state>
        <zip>33012</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigational Site</name>
      <address>
        <city>Sant Cugat</city>
        <state>Catalunya</state>
        <zip>08190</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigational Site</name>
      <address>
        <city>Barcelona</city>
        <zip>08021</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigational Site</name>
      <address>
        <city>Barcelona</city>
        <zip>8022</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigational Site</name>
      <address>
        <city>Zaragoza</city>
        <zip>50009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Austria</country>
    <country>Bulgaria</country>
    <country>France</country>
    <country>Hungary</country>
    <country>Israel</country>
    <country>Japan</country>
    <country>Latvia</country>
    <country>Lithuania</country>
    <country>Poland</country>
    <country>Portugal</country>
    <country>Slovakia</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>April 15, 2021</study_first_submitted>
  <study_first_submitted_qc>April 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 29, 2021</study_first_posted>
  <last_update_submitted>November 17, 2021</last_update_submitted>
  <last_update_submitted_qc>November 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
    <mesh_term>Wet Macular Degeneration</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

